Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$60.95

-0.46 (-0.75%)

, SMMT

Summit Therapeutics

$8.65

-0.414 (-4.57%)

07:08
10/04/16
10/04
07:08
10/04/16
07:08

Sarepta, Summit enter into exclusive license, collaboration agreement

Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy, or DMD. As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries. Utrophin modulation is a potential disease-modifying treatment for all patients with the fatal muscle wasting disease DMD, regardless of their underlying dystrophin gene mutation. Ezutromid is currently in a Phase 2 proof of concept trial called PhaseOut DMD. Under the terms of the agreement, Summit will receive an upfront fee of $40M. In addition, Summit will be eligible for future ezutromid related development, regulatory and sales milestone payments totalling up to $522M, including a $22M milestone upon the first dosing of the last patient in Summit's PhaseOut DMD trial, and escalating royalties ranging from a low to high teens percentage of net sales in the licensed territory.

SRPT

Sarepta

$60.95

-0.46 (-0.75%)

SMMT

Summit Therapeutics

$8.65

-0.414 (-4.57%)

  • 06

    Nov

SRPT Sarepta
$60.95

-0.46 (-0.75%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $64
PIPR
Overweight
Sarepta stock issuance strengthens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics has a strengthened balance sheet after issuing 5.02M shares at a price of $59.75. Further, for its Exondys51 approval, Sarepta gained a Rare Priority Review Voucher that could be sold to further pad the company's cash position, Tenthoff tells investors in an intraday research note. He reiterates an Overweight rating on the shares with a $64 price target. The stock is down 5% to $57.74 in late afternoon trading.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
SMMT Summit Therapeutics
$8.65

-0.414 (-4.57%)

02/01/16
ADAM
02/01/16
INITIATION
Target $14
ADAM
Buy
Summit Therapeutics initiated with a Buy at Canaccord
Target $14.
02/01/16
02/01/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.
06/21/16
JANY
06/21/16
INITIATION
Target $15
JANY
Buy
Summit Therapeutics initiated with a Buy at Janney Capital
Janney Capital analyst Debjit Chattopadhyay started coverage of Summit Therapeutics with a Buy rating and $15 fair value estimate as he believes the company's pre-clinical data has been compelling and that two upcoming data reads should clarify its outlook and provide a catalyst for the stock.
09/16/16
HCWC
09/16/16
INITIATION
Target $26
HCWC
Buy
Summit Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther initiated Summit Therapeutics with a Buy and a $26 price target saying Ezutromid in DMD can potentially generate $1.2B in global sales in FY26.

TODAY'S FREE FLY STORIES

LIOX

Lionbridge

16:58
02/26/17
02/26
16:58
02/26/17
16:58
Conference/Events
Lionbridge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$37.89

0.24 (0.64%)

, CMCSK

Comcast

16:54
02/26/17
02/26
16:54
02/26/17
16:54
Hot Stocks
Box Office Battle: Comedy horror 'Get Out' thrills in $31M opening »

Comcast's (CMCSA)…

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

TWX

Time Warner

$97.28

0.6225 (0.64%)

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

DIS

Disney

$110.32

0.59 (0.54%)

FOX

21st Century Fox

$30.23

0.23 (0.77%)

FOXA

21st Century Fox

$30.61

0.27 (0.89%)

VIA

Viacom

VIAB

Viacom

$43.89

0.03 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

WAT

Waters

$156.40

1.51 (0.97%)

16:38
02/26/17
02/26
16:38
02/26/17
16:38
Conference/Events
Waters to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 01

    Apr

CR

Crane

$73.21

1.18 (1.64%)

16:36
02/26/17
02/26
16:36
02/26/17
16:36
Conference/Events
Crane to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

16:34
02/26/17
02/26
16:34
02/26/17
16:34
Hot Stocks
LSE rejects European Commission merger demand, says unlikely to approve deal »

London Stock Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCO

Brink's

$52.00

0.7 (1.36%)

16:33
02/26/17
02/26
16:33
02/26/17
16:33
Conference/Events
Brink's to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

XOM

Exxon Mobil

$81.08

-0.7 (-0.86%)

16:28
02/26/17
02/26
16:28
02/26/17
16:28
Conference/Events
Exxon Mobil to host analyst meeting with a conference call hook-up »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.84

0.2 (3.55%)

16:22
02/26/17
02/26
16:22
02/26/17
16:22
Conference/Events
TherapeuticsMD to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 21

    Mar

  • 07

    May

MYL

Mylan

$42.16

-0.17 (-0.40%)

16:19
02/26/17
02/26
16:19
02/26/17
16:19
Conference/Events
Mylan to host investor day with a conference call hook-up »

CEO Bresch holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 28

    Mar

  • 03

    Sep

  • 09

    Oct

MCD

McDonald's

$128.65

0.38 (0.30%)

16:16
02/26/17
02/26
16:16
02/26/17
16:16
Conference/Events
McDonald's to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$108.90

0.25 (0.23%)

16:13
02/26/17
02/26
16:13
02/26/17
16:13
Conference/Events
Hershey to hold a webcast »

Incoming CEO Michelle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

16:10
02/26/17
02/26
16:10
02/26/17
16:10
Hot Stocks
Samsung introduces Gear VR with controller »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SSNLF

Samsung

16:08
02/26/17
02/26
16:08
02/26/17
16:08
Hot Stocks
Samsung announces Galaxy Tab S3, Galaxy Book tablets »

Samsung announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

SSNLF

Samsung

, HAR

Harman

$111.44

0.34 (0.31%)

16:06
02/26/17
02/26
16:06
02/26/17
16:06
Hot Stocks
Samsung, Harman announce audio collaboration for Galaxy devices »

Samsung (SSNLF) and…

SSNLF

Samsung

HAR

Harman

$111.44

0.34 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

EFX

Equifax

$129.38

0.16 (0.12%)

16:06
02/26/17
02/26
16:06
02/26/17
16:06
Conference/Events
Equifax management to meet with investors »

CFO Gamble to meet with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 01

    Mar

MRK

Merck

$66.16

0.31 (0.47%)

16:03
02/26/17
02/26
16:03
02/26/17
16:03
Hot Stocks
Merck says Phase 3 letermovir study meets primary efficacy goal »

Merck announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 15

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

EFX

Equifax

$129.38

0.16 (0.12%)

16:03
02/26/17
02/26
16:03
02/26/17
16:03
Conference/Events
Equifax management to meet with investors »

Chairman & CEO Smith,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOK

Nokia

$5.14

-0.01 (-0.19%)

15:58
02/26/17
02/26
15:58
02/26/17
15:58
Hot Stocks
Nokia announces expanded portfolio of digital health products, solutions »

Nokia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 23

    May

TGT

Target

$66.51

1.53 (2.35%)

15:45
02/26/17
02/26
15:45
02/26/17
15:45
Conference/Events
Target to hold a financial community meeting »

Management holds 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 19

    Mar

GPRO

GoPro

$9.43

-0.14 (-1.46%)

15:42
02/26/17
02/26
15:42
02/26/17
15:42
Hot Stocks
GoPro says 'Quik' app chosen by Huawei for latest devices »

GoPro announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LGND

Ligand

$100.38

-2.46 (-2.39%)

15:40
02/26/17
02/26
15:40
02/26/17
15:40
Conference/Events
Ligand to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

HURN

Huron

$44.30

-0.8 (-1.77%)

15:39
02/26/17
02/26
15:39
02/26/17
15:39
Conference/Events
Huron to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ENS

EnerSys

$75.98

-0.77 (-1.00%)

15:36
02/26/17
02/26
15:36
02/26/17
15:36
Conference/Events
EnerSys to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 17

    Mar

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

15:36
02/26/17
02/26
15:36
02/26/17
15:36
Hot Stocks
Ericsson says selected by Batelco for mobile network enhancement »

Ericsson announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 29

    Mar

QCOM

Qualcomm

$57.22

0.08 (0.14%)

15:33
02/26/17
02/26
15:33
02/26/17
15:33
Conference/Events
Qualcomm to hold an investor session at Mobile World Congress 2017 »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.